Published in Cardiovascular Business Week, November 15th, 2005
The program was acquired through GenVec's 2003 merger with Diacrin, Inc.
Under the terms of the nonbinding agreement, GenVec will assign all key licenses and use agreements relating to the program to a newly formed company in exchange for a royalty on all future product and process sales revenue or license sales revenue generated from the program.
GenVec and the buyer are finalizing agreements to complete the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.